In this episode of the Vital Signs podcast, host Stef van Grieken, co-founder and CEO of Cradle Bio, shares insights into the evolving role of AI in biotechnology. He notes that the field is still in its infancy, comparable to the early stages of GPT technology. Cradle Bio leverages AI to significantly speed up protein development, achieving impressive enhancements of 1.2 to 12 times faster across various stages, from hit identification to Investigational New Drug (IND) applications. Their successful SaaS model is making waves in the pharmaceutical industry by emphasizing measurable results and strategic impact. Looking ahead, Cradle Bio plans to tackle more complex protein types, enhance zero-shot learning capabilities, and improve data sharing and standardization within the biotech sector.
